{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T11:59:44Z","timestamp":1761393584588},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,8,1]]},"DOI":"10.1097\/qai.0b013e318074eff5","type":"journal-article","created":{"date-parts":[[2007,6,6]],"date-time":"2007-06-06T08:03:46Z","timestamp":1181117026000},"page":"401-410","source":"Crossref","is-referenced-by-count":20,"title":["Long-Term Efficacy and Safety of Tipranavir Boosted With Ritonavir in HIV-1-Infected Patients Failing Multiple Protease Inhibitor Regimens"],"prefix":"10.1097","volume":"45","author":[{"given":"Martin","family":"Markowitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard N","family":"Slater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Powel H","family":"Kazanjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Hathaway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietmar","family":"Neubacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Mayers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hernan","family":"Valdez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"McCallister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210131","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/jama.288.2.222","article-title":"Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.","volume":"288","author":"Yeni","year":"2002","journal-title":"JAMA"},{"key":"R2-4-20210131","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/archinte.159.15.1771","article-title":"Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome.","volume":"159","author":"Valdez","year":"1999","journal-title":"Arch Intern Med"},{"key":"R3-4-20210131","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-131-2-199907200-00002","article-title":"Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions.","volume":"131","author":"Lucas","year":"1999","journal-title":"Ann Intern Med"},{"key":"R4-4-20210131","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1086\/344358","article-title":"Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study.","volume":"186","author":"Masquelier","year":"2002","journal-title":"J Infect Dis"},{"key":"R5-4-20210131","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1128\/JVI.77.8.4836-4847.2003","article-title":"Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments.","volume":"77","author":"Wu","year":"2003","journal-title":"J Virol"},{"key":"R6-4-20210131","doi-asserted-by":"crossref","first-page":"F17","DOI":"10.1097\/00002030-199902040-00001","article-title":"Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study.","volume":"13","author":"Lorenzi","year":"1999","journal-title":"AIDS"},{"key":"R7-4-20210131","doi-asserted-by":"crossref","first-page":"401","DOI":"10.7326\/0003-4819-122-6-199503150-00001","article-title":"Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B\/117 Team and the Virology Committee Resistance Working Group.","volume":"122","author":"DAquila","year":"1995","journal-title":"Ann Intern Med"},{"key":"R8-4-20210131","doi-asserted-by":"crossref","first-page":"813","DOI":"10.7326\/0003-4819-131-11-199912070-00003","article-title":"HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.","volume":"131","author":"Zolopa","year":"1999","journal-title":"Ann Intern Med"},{"key":"R9-4-20210131","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1089\/aid.2005.21.343","article-title":"Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance.","volume":"21","author":"Daar","year":"2005","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R10-4-20210131","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/01.qai.0000138420.38995.86","article-title":"Tolerability and safety of HIV protease inhibitors in adults.","volume":"37","author":"Sax","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R11-4-20210131","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00126334-200312010-00008","article-title":"Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort.","volume":"34","author":"OBrien","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 2","key":"R12-4-20210131","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1086\/381447","article-title":"Liver toxicity in epidemiological cohorts.","volume":"38","author":"Becker","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R13-4-20210131","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1097\/00002030-200411190-00008","article-title":"Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.","volume":"18","author":"Sulkowski","year":"2004","journal-title":"AIDS"},{"key":"R15-4-20210131","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/(SICI)1097-0282(1999)51:1<51::AID-BIP6>3.0.CO;2-U","article-title":"Structure-based discovery of tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor.","volume":"51","author":"Thaisrivongs","year":"1999","journal-title":"Biopolymers"},{"key":"R16-4-20210131","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1021\/jm9802158","article-title":"Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class.","volume":"41","author":"Turner","year":"1998","journal-title":"J Med Chem"},{"key":"R18-4-20210131","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1097\/00002030-200009080-00009","article-title":"Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.","volume":"14","author":"Larder","year":"2000","journal-title":"AIDS"},{"key":"R19-4-20210131","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00002030-200001070-00019","article-title":"In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors.","volume":"14","author":"Back","year":"2000","journal-title":"AIDS"},{"key":"R20-4-20210131","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1128\/AAC.44.5.1328-1332.2000","article-title":"Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.","volume":"44","author":"Rusconi","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-4-20210131","first-page":"S16","article-title":"Characterization of treatment-emergent resistance mutations in two phase II studies of tipranavir [abstract].","volume":"8","author":"Hall","year":"2003","journal-title":"Antivir Ther"},{"key":"R23-4-20210131","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00002030-200101260-00007","article-title":"Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.","volume":"15","author":"Mocroft","year":"2001","journal-title":"AIDS"},{"key":"R25-4-20210131","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/0091270005283279","article-title":"Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies.","volume":"46","author":"Boffito","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R27-4-20210131","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0140-6736(06)69154-X","article-title":"Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.","volume":"368","author":"Hicks","year":"2006","journal-title":"Lancet"},{"key":"R28-4-20210131","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1086\/508352","article-title":"Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.","volume":"43","author":"Cahn","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R29-4-20210131","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1086\/508353","article-title":"Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.","volume":"43","author":"Gathe","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R30-4-20210131","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1086\/339014","article-title":"Safety and antiviral activity at 48 weeks of lopinavir\/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.","volume":"185","author":"Benson","year":"2002","journal-title":"J Infect Dis"},{"key":"R31-4-20210131","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.","volume":"348","author":"Lalezari","year":"2003","journal-title":"N Engl J Med"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00126334-200708010-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T07:19:34Z","timestamp":1618039174000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-200708010-00004"}},"subtitle":["80-Week Data From a Phase 2 Study"],"short-title":[],"issued":{"date-parts":[[2007,8,1]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e318074eff5","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8,1]]}}}